A comparative study of the frequency of antibody and titers against human herpesvirus 8 latent and lytic antigens in “at-risk” individuals and among patients with Kaposi's sarcoma

✍ Scribed by Mariana Cavalheiro Magri; Paulo Henrique Lage Carbone; Elizabeth de los Santos-Fortuna; Adele Caterino-de-Araujo

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 87 KB
• Volume: 81
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.21513

✦ Synopsis

Abstract

Differences in the prevalence of human herpesvirus 8 (HHV‐8) and Kaposi's sarcoma (KS) have been described, depending on the study population and their geographic origin. A cross‐ sectional study aimed at detecting the frequency and titers of antibodies against HHV‐8 latent and lytic antigens in serum samples from individuals with different risk‐factors for HHV‐8 infection, as well as predictive marker identification in patients with KS, was conducted. Serum samples were collected from seven groups of individuals: 75 patients with AIDS‐KS, 5 with classic KS, 16 with African KS, 495 with HIV/AIDS, 805 patients with chronic kidney disease, 683 handicapped individuals, and 757 health care workers. Samples were evaluated for the presence and titers of HHV‐8‐specific antibodies to latent and lytic antigens using “in house” immunofluorescence assays. The results were analyzed by the Chi‐square, Fisher's exact test, Kruskal–Wallis and/or Mann–Whitney U‐tests. The frequencies of HHV‐8 antibodies were as follows: 87.5–100% in patients with KS, 20.4% in patients with HIV/AIDS, 18% in patients with chronic kidney disease, 1.6% in handicapped individuals, and 1.1% in health care workers. A greater number of samples were antibody positive to lytic antigens. Elevated titers of antibodies to latent and lytic antigens, mostly among patients with KS, were detected. Using established serological assays, different “at‐risk” populations for HHV‐8 infection/disease were detected in this geographic area, confirming HIV/AIDS and identifying patients with chronic kidney disease as high‐risk groups. It is suggested that a longitudinal evaluation of antibody titers in patients with chronic kidney disease be undertaken to confirm their predictive value in the development of KS. J. Med. Virol. 81:1292–1297, 2009. © 2009 Wiley‐Liss, Inc.